Fast track designation

Fast Track Designation
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis	N/A
Prevention	N/A
Treatment
Medication
Prognosis
Frequency
Deaths	N/A

Fast Track Designation is a process designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet medical need. This designation is granted by the United States Food and Drug Administration (FDA) and is intended to get important new drugs to the patient earlier.

Overview

Fast Track Designation is part of the FDA's efforts to speed up the availability of new treatments for serious conditions. The designation is intended to help drug developers bring new therapies to market more quickly by providing more frequent interactions with the FDA and allowing for a rolling review of the drug's marketing application.

Criteria for Fast Track Designation

To qualify for Fast Track Designation, a drug must meet two main criteria:

1. The drug must be intended to treat a serious condition.
2. The drug must demonstrate the potential to address unmet medical needs.

A serious condition is defined as a disease or condition associated with morbidity that has substantial impact on day-to-day functioning. Unmet medical needs refer to conditions where there is no current therapy or where the new drug may provide a significant improvement over existing treatments.

Benefits of Fast Track Designation

Fast Track Designation offers several benefits to drug developers, including:

• More frequent meetings with the FDA: This allows for more guidance and feedback from the FDA during the drug development process.
• More frequent written communications from the FDA: This includes advice on the design of proposed clinical trials and the use of biomarkers.
• Eligibility for Accelerated Approval and Priority Review: If the drug meets certain criteria, it may also qualify for these additional expedited programs.
• Rolling Review: This allows a drug company to submit completed sections of its New Drug Application (NDA) or Biologics License Application (BLA) for review by the FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed.

Application Process

The process for obtaining Fast Track Designation involves submitting a request to the FDA. This request can be made at any time during the drug development process, but it is typically done after some initial clinical data is available. The request should include:

• A description of the drug and the serious condition it is intended to treat.
• Evidence that the drug has the potential to address unmet medical needs.
• A summary of the drug's development plan.

The FDA will review the request and make a decision based on the information provided. If granted, the Fast Track Designation will be communicated to the drug developer, and the benefits of the program will be available immediately.

Examples of Fast Track Designation

Many drugs have been granted Fast Track Designation over the years, particularly those targeting cancer, rare diseases, and infectious diseases. Some notable examples include:

• Drugs for the treatment of HIV/AIDS.
• Therapies for cystic fibrosis.
• Treatments for various types of cancer.

Conclusion

Fast Track Designation is a valuable tool for drug developers seeking to bring new therapies to market more quickly. By facilitating more frequent interactions with the FDA and allowing for a rolling review process, this designation helps ensure that patients with serious conditions have access to new treatments as soon as possible.

See Also

• Accelerated Approval
• Priority Review
• Breakthrough Therapy Designation

External Links

• [FDA Fast Track Designation Overview](https://www.fda.gov)